Research programme: mutant KRAS-targeted inhibitors - Quanta Therapeutics
Alternative Names: RAS inhibitors - Quanta Therapeutics; RAS-targeted inhibitors - Quanta TherapeuticsLatest Information Update: 24 Nov 2021
At a glance
- Originator Quanta Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 28 Oct 2021 Quanta Therapeutics intends to file an IND application with a regulatory body for Cancer
- 28 Oct 2021 Pharmacodynamics data from a research study in Cancer released by Quanta Therapeutics
- 26 Oct 2021 Preclinical trials in Cancer in USA (unspecified route) (Quanta Therapeutics pipeline, October 2021)